Assenagon Asset Management S.A. Trims Holdings in Illumina, Inc. $ILMN

Assenagon Asset Management S.A. decreased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 28.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 23,235 shares of the life sciences company’s stock after selling 9,246 shares during the period. Assenagon Asset Management S.A.’s holdings in Illumina were worth $3,048,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. True Wealth Design LLC boosted its position in shares of Illumina by 21.8% in the fourth quarter. True Wealth Design LLC now owns 2,272 shares of the life sciences company’s stock worth $298,000 after purchasing an additional 407 shares during the period. Wealth Enhancement Advisory Services LLC raised its position in shares of Illumina by 15.4% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 105,237 shares of the life sciences company’s stock valued at $13,803,000 after purchasing an additional 14,072 shares during the period. NorthCrest Asset Manangement LLC lifted its stake in shares of Illumina by 75.8% during the 4th quarter. NorthCrest Asset Manangement LLC now owns 11,296 shares of the life sciences company’s stock valued at $1,597,000 after buying an additional 4,871 shares in the last quarter. Grove Bank & Trust lifted its stake in shares of Illumina by 1,990.5% during the 4th quarter. Grove Bank & Trust now owns 1,756 shares of the life sciences company’s stock valued at $230,000 after buying an additional 1,672 shares in the last quarter. Finally, Wedmont Private Capital boosted its holdings in Illumina by 7.8% in the 4th quarter. Wedmont Private Capital now owns 2,497 shares of the life sciences company’s stock worth $328,000 after buying an additional 181 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Piper Sandler cut their price target on Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research note on Monday, February 9th. Weiss Ratings restated a “hold (c-)” rating on shares of Illumina in a research report on Monday, December 29th. Stifel Nicolaus upped their price objective on Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. TD Cowen reiterated a “hold” rating on shares of Illumina in a research report on Wednesday, January 7th. Finally, Wall Street Zen raised Illumina from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 14th. Six analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Illumina currently has an average rating of “Hold” and a consensus target price of $129.69.

Insider Buying and Selling at Illumina

In other news, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total value of $275,346.60. Following the sale, the senior vice president directly owned 16,321 shares in the company, valued at $1,896,173.78. The trade was a 12.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.17% of the stock is currently owned by company insiders.

Illumina Stock Up 2.7%

NASDAQ ILMN opened at $120.81 on Tuesday. The stock has a 50 day moving average price of $128.39 and a 200-day moving average price of $122.02. Illumina, Inc. has a one year low of $68.70 and a one year high of $155.53. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. The company has a market capitalization of $18.47 billion, a P/E ratio of 22.17, a P/E/G ratio of 2.25 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.09. The company had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.10 billion. Illumina had a net margin of 19.57% and a return on equity of 31.04%. Illumina’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, equities analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.